Melfalan Teva

Melphalan hydrochloride, the active ingredient in Melfalan Teva, is an alkylating agent presented as a solution for injection for intravenous use. It treats certain cancers such as multiple myeloma, ovarian cancer, melanoma and urothelial carcinoma in adult patients.

GNH USA supplies Melfalan Teva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melfalan Teva is an alkylating chemotherapy agent used in the treatment of several solid‑tumor and hematologic malignancies.

Multiple Myeloma: used in combination regimens to achieve disease control and extend survival. Ovarian Cancer: administered as part of salvage therapy to reduce tumor burden. Melanoma: employed in advanced disease when other options are limited. Urothelial Carcinoma: incorporated into systemic treatment protocols for refractory cases.

Melfalan Teva may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue - Myelosuppression (decreased blood cell counts) - Alopecia (hair loss)

Serious or Rare Side Effects: - Secondary malignancies (new cancers) - Severe infections due to immune suppression - Pulmonary toxicity (lung inflammation or fibrosis)

Prior to initiating therapy, several safety considerations should be observed.

Monitor blood counts: perform regular CBC to detect myelosuppression. Assess renal function: adjust therapy if creatinine clearance is reduced. Evaluate pulmonary status: watch for signs of lung toxicity. Avoid use in pregnancy: teratogenic risk requires effective contraception. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: additive myelosuppression. - Live attenuated vaccines: increased risk of infection. - High‑dose radiation therapy: heightened tissue damage.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., 5‑HT3 antagonists): may alter nausea control. - Renally cleared drugs (e.g., aminoglycosides): monitor renal function. - Sulfonamides: potential increase in bone‑marrow suppression.